Hence the conclusion can be drawn, that RhoA/ROCK and the corresponding downstream effector molecules might be suitable targets to develop new therapeutic approaches for the treatment of autoimmune diseases, such as MS [186,187,188,189]. Here, RHOA is linked to myeloid sarcoma.